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Summar£ 
Stimulated labeling of phospholipids from 32p i is a hallmark 
of activation of a variety of cell surface receptors. In the 
case of the central nervous system, the response can ref lect 
muscarinic activation. Recent studies in nerve ending prepara- 
tions indicate a postsynaptic site of action. Ca 2+ is re- 
quired for the expression of cholinergic stimulation of label- 
ing in nerve ending preparations, but whether i t  plays a regula- 
tory role is not yet known. While i t  Is inferred that the re- 
ceptor-I igand i nteraction Ieads to increased diacylglycerol 
avai labi l i ty ,  i ts  source is not established. In experiments 
with muscarinic agents and ionophore added to nerve ending pre- 
parations, there is a potentiated loss of labeling from prela- 
beled polyphosphoinositides. I t  is suggested that phosphodi- 
esteratic cleavage of polyphosphoinositides may be an early 
consequence of muscarinic receptor activation. 
Phosphatidyl i nositol {Phl) is 1,2-di acyl -sn-glyc ero{ 3)- pho spho( l )-D-nlyo- 
Inositol (Fig. IA). Much confusion over the no~nclature of the cyclitols and 
their lipids can be attributed to the previous use of mutually incompatible 
numbering systems (1). In recent hi story, the IUPAC Con~nlssion on 
Nomenclature renamed as D-l-m£o-inositol l-phosphate what had up until then 
been called the L-l-phosphate (2). The confusion was again compounded by a 
mix-up in the 1977 Commission report (3,4). The reader can at once be 
liberated of these past problems by examining Fig. IB. It can be seen that 
the chair form of n~yo-inositol consists of one axial and five equatorial 
hydroxyls. If we imagine t~ molecule to be in the shape of a turtle with the 
axial hydroxyl (D-2) as its head, then the right front paw is D-l, the 
position phosphodiesterified to glycerol in inosltol lipids. Higher 
inositides are additionally monoesterlfied with phosphate at D-4 (the left 
hind leg) or D-4 and D-5 (the tail), yielding phosphatidylinositol 4-phosphate 
(PhlP), or phosphatidyllnositol 4,5-bisphosphate (PhlP2), respectively. It 
is of interest from the structural standpoint that although there are nine 
possible stereolsomers of hexahYdroxycyclohexane, the m£o isomer is by far the 
most prevalent and the only cyclitol isomer known to occur in a natural 
phosphatlde. The polyphosphoinositides, PhlP and PhlP?, are present in cell 
membranes in much lower amounts than Phl. Much recent interest in Phl and its 
derivatives relate to the high proportion of arachidonate (20:4~ 6 cls) in the 
2 position of the glycerol moiety of the phospholnosltldes, since arachldonate 
is a known precursor of physiologically important prostanoids (5). 
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FIG. | 
A. Structure of phosphatidylinosito|. The naturally occurring l ip id  is 
enriched in stearate in R' and arachidonate in R". B. The tur t le 's  head is 
axial whi|e i ts legs and tai l  are equatorial hydroxy]s of myo-inositol in the 
prevalent chair form. The phosphatidyl group is attached--a~c the D-l (r ight 
forepaw) in all of the phosphoinositides. See text.  
Stimulated l i p i d  label ing. The stimulated labeling by 32p i of Phl and of 
phosphatidate (PhA) by incubation of various t issue preparations in the 
presence of ligands for which they have cel l  membrane receptors has been known 
for t h i r t y  years. For example, when carbamylcholine wa~ added to pancreas 
sl ices,  PhA and Phl showed increased incorporation of J~Pi present in the 
incubation medium (6). The stimulation could be blocked by atropine, a known 
muscarinic cholinergic receptor antagonist. Our interest  several years ago in 
the possible metabolic relat ionship between PhA and Phl led to the discovery 
that Phl is biosynthesized by the transfer of the phosphatidyl moiety from the 
l iponucleotide CDP-diacylglycerol to myo-inositol ,  with the l iberat ion of CMP 
(7,8) .  The l iponuc]eotide was s u b s ~ e n t l y  found to be formed from the 
enzymatic reaction of CTP with PhA (9,10). In de novo biosynthesis (Fig. 2), 
PhA is formed from fatty acyl CoA and glycerol--phos-6-~p ate or dihydroxyacetone 
phosphate ( l l ) .  Labeled PhA can also form by the action of diacylglycerol 
kinase on 32p-ATP and diacylglycerol_ which arises from degradation of a 
number of preexisting l ip ids.  Thus :~2P i added to an incubation medium is 
converted intracel lular ly to 32p-ATP and i f  diacylglycerol is available, 
labeled PhA and Phl wi l l  be formed. When incorporation of precursors of de 
novo l ip id  synthesis is measured under  conditions in which 32~ T 
incorporation into PhA and Phl is stimulated, a comparable stimulation of 
incorporation of label relative to the basal rate from glucose or glycerol is 
~ t  seen (12). The results indicate that the stimulated incorporation of 
i is more l ikely accounted for by phosphorylation of endogenously 
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Biosynthetic scheme of phosphol ipids i l lustrat ing precursor-product 
relationship of PhA and Phl. Dihydroxyacetone phosphate (DHAP) may be reduced 
to GP and be sequentially acylated to PhA, or alternatively, acylated in the l 
position, reduced to acyl DHAP and acylated to form PhA. Acylation steps are 
starred. CDP-di acyl glycerol al so serves as a precursor of the 
phosphatidylglycerols (PhG). PhA can be dephosphorylated to diacylglycerol, 
which t hen  serves as precursor of pho sphati dyl ethanol amine (PhE), 
phosphatidylcholine (PhC) and triglycerides. 
generated diacylglycerol than by de novo biosynthesis of PhA and Phl. The 
production of diacylglycerol from-~3-reexisting l ipid may then play a key role 
in stimulated labeling. A specific phespholipase that cleaves Phl to 
diacylglycerol and inositol monophosphate (a mixture of myo-inositol D-l 
phosphate and D I-2 cyclic phosphate) has been characterize-d~(13). I f  the 
I iga rid-receptor interaction directly or indirectly stimulates this 
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When an acidic extraction method is used in such labeling experiments, two 
additional labeled phospholipids are extracted: PhIP and PhIP 2. These 
po ly pho sphoi nosi t i  des are highly ]abeled by 32p i in their monoester 
moieties, rather than in the phosphodiester, as a result of the actions of 
specific kinases and phosphatases that catalyze the reactions: P h I ~  PnIP "~-- 
PhIP 2. As is discussed below, the polyphosphoinositides may play an 
important role in the mechanism of stimulated l ip id  labeling. 
Studies in synaptosomes. The widespread occurrence among tissues of 
stimulated l ip id  labeling is well-documented (]4).  In addition to the 
pancreas, systems frequently employed to study this effect include the action 
of chemotactic peptide on leukocytes (15), of muscarinic agents on the avian 
salt gland (16), of vasopressin on hepatocytes (17), of thyrotropin on thyroid 
(18) and of thrombin on platelets (19). In genera], the stimulated PhA-Phl 
labeling does not appear to involve cyclic nucleotide mechanisms or 
phospholipid methylation (20). In tissues in which the ]igand-receptor 
interaction results in secretion, molar effects can be seen in the measured 
chemical amounts of phospholipids. For example, upon addition of ACh or 
pancreazymin to pancreatic acinar cel ls,  Phl content is decreased and PhA 
increases (21). The secretory preparations suffer from the disadvantage that 
i t  is d i f f i cu l t  to easily separate the quantitatively minor alterations in 
phospholipid metabolism attributable to signal transduction from those related 
to the subsequent secretory events. The various effector cell systems share 
the common property that they must be intact: once cel ls have been broken 
open, stimulated labeling can no longer be e l ic i ted.  The abi l i ty  of brain 
homogenates to retain an ACh-sensitive stimulated labeling effect can be 
attributed to the presence of nerve endings. These broken-off bits of 
neuronal terminals (synaptosomes) resea] into particles which may be 
considered anucleate neurons--they contain mitochondri a, endopl asmic 
reticulum, and synaptic vesicles, etc. under conditions that maintain the 
vectorial properties of the plasma membrane. Studies in our laboratory have 
established that a " l ight"  nerve ending fraction mediates the stimulated 
labeling (22). 
In general, two types of experiments can be performed. In the f i r s t ,  one 
]abels nerve ending preparations in an in i t ia l  incubation and then examines 
increases or decreases in the prelabeled l ip id following addition of ligands, 
blockers, etc. during a subsequent incubation period. In the second approach, 
32p i can be added together with the vari ou s drugs to un] abel ed 
preparations at the onset of the incubation. Using the la t ter  paradigm, we 
found that the addition of lO -4 to IO-3M ACh or carbamylcholine results in 
an atropine-sensitive increase in labeled PhA (about I00% stimulation) and Phl 
(about 70% stimulation) over a 30 minute period (22). PhIP and PhIP 2 are 
also highly labeled, but incorporation is not stimulated by muscarinic 
agonists. The stimulatory effects on PhA and Phl labeling are not acco~anied 
by a change in the specific act iv i ty of intracel lular 32p-ATP, and thus 
represent increased turnover of the various I~hospholipids (23). I f  nerve 
endings are labeled in the presence or absence of ]igand and then ]ysed and 
fractionated, the stimulated labeling can be shown to be localized to a plasma 
membrane-rich fraction (24). Ionophores mimic the cholinergic-stimulated 
labeling in nerve ending preparations, and their action can be blocked by the 
addition of EGTA. The combined presence of ionophore A23187 and 
carbamylcholine leads to a potentiation of the stimulation of PhA and Phl 
labeling (25), and a stimulated decrease in PhIP and PhIP 2 labeling is now 
seen (]2). The addition of EGTA blocks the stimulation of l ip id  labeling by 
carba~b, lcholine, but the addition of atropine does not block the stimulator), 
effect of ionophore addition. In fact, when atropine is added to a medium 
containing both ionophore and carbamylcholine, the degree of stimulation 
reverts to that obtained with the addition of ionophore alone (12). The 
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results may be interpreted to indicate that Ca 2+ mobil ization is  a d i rect  
consequence of the receptor-ligand interact ion and precedes (and perhaps 
mediates) the stimulation of l i p i d  label ing. While the findings are 
compatible with this in terpretat ion,  i t  should be cautioned that they indicate 
only that some basal Ca Z+ level i s  necessary for the expression of the 
stimulated labeling, and do not necessarily indicate that Ca Z+ is regulating 
the rate of l ipid turnover. We have examined directly the possibility that 
Ca 2+ fluxes are altered in nerve endings treated with muscarinic agents, and 
have found no evidence in support of this (L.A.A. Van Rooijen and B.W. 
Agranoff, in preparation). 
The ionophore experiments in nerve endings indicate an interact ion of the 
activated cholinergic receptor and Ca 2+, which may well be transmembrane in 
nature. More generally, a relat ionship between stimulated l i p i d  labeling and 
Ca2+ has been inferred in a l l  t issues that support stimulated l i p i d  
label ing, although i t s  exact nature has yet  to be defined. Since the cytosol 
is  compartmented from mitochondrial and extracel lu lar  stores of CaZ+ whose 
concentration of Ca 2+ are orders of magnitude greater, and since l i p i d  
labeling from 32p i can be evoked by tonophores that increase in t race l lu la r  
Ca2+, i t  is  tempting to speculate that the receptor-ligand interact ion 
i n i t i a t es  a cascade which elevates cytosol ic calcium. PhA i t s e l f  has been 
shown to be a Ca2+ tonophore (26). Since the production of dfacylglycerol 
may be Ca2+-dependent, i t s  release and resynthesis to PhA could be part of 
an ampli f icat ion mechanism whereby large amounts of Ca2+ are mobilized. The 
demonstration of a protein kinase that is  activated by diacylglycerol (27) 
also suggests the part ic ipat ion of a regulatory process. Of further possible 
relevance is the B-50 protein whose phosphorylation is  believed to regulate 
the ac t i v i t y  of PhlP kinase (28). Polyphosphoinositides are known to bind 
Ca2 + t i gh t l y ,  hence thei r  metabolism could lead to altered local Ca2+ 
ava i l ab i l i t y  in the region of the plasma membrane. A breakdown of 
polyphosphoinositides was observed upon muscarinic stimulation of i r i s  muscle 
(29) and has also been seen in synaptosomes (30), par t icu lar ly  combined in the 
presence of ionophore plus muscarinic agonist (12). More recently, the 
specif ic breakdown of PhlP 2 has been reported in stimulated parotid gland 
(31). This suggests that the labeling cycle may be extended as follows: 
Ph I P2 Di acyl glycerol 
In the case of nerve endings, there is  no known secretory or contract i le  
process associated with the addition of muscarinic agents and no clear 
indicat ion of the functional signif icance of the stimulated label ing. 
Interest in the ef fect  is  however high, since the phenomenon represents a rare 
biochemical "handle" of the act ivat ion of a CNS muscarintc receptor. The 
potential relevance of the phenomenon to brain function is  exemplified by the 
recent demonstration of selective loss of cholinergic f ibers in the cortex in 
Alzheimer's disease (32). 
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FIG. 3 
Diagram of synaptic arrangements in brain that could give rise to nerve 
endings containing integral postsynaptic membranes. See text. 
We have pursued the question of whether the effect is pre- or postsynaptic. 
The "typical" synaptosome, as we might encounter i t  in a textbook, is a round 
bag containing mitochondria and synaptic vesicles and may have an attached 
synaptic complex, including a b i t  of postsynaptic membrane of i ts  Former 
neighboring neuron. S ince  32p i is converted to ~ 32p-~TP inside the 
resealed nerve ending, one may be led to conclude that the stimulated labeling 
is presynaptic: 3ZP i enters the nerve ending, is converted to v32p-ATP 
and then enters l ip ids via cytosolic or men~)rane-bound diacylglycerol kinase 
or Phl/PhIP kinases. By analogy with experiments in non-brain preparations in 
which cholinergic stimulation leads to secretion, however, one would expect 
the effect to be postsynaptic. In order to reconcile these opposing 
interpretations, we examined the two possibi l i t ies by means of hippocampal 
lesions in the guinea pig brain. Fimbrial lesions block the major cholinergic 
input to the hippocampus, but are presumed to leave intact the postsynaptic 
cholinoceptive surfaces (33). Intracerebral injections of the excitatory 
toxin ibotenate, on the other hand, should destroy int r ins ic  neurons (and 
their postsynaptic receptor surfaces) and leave the cholinergic presynaptic 
terminals from the septa] nuclei intact (34). The val id i ty  of these 
assumptions was tested with known markers for the pre- and postsynaptic 
terminals: cholineacetyltransferase act iv i ty  and quinuclidinyl benzilate 
(QNB) binding, respectively. The stimulated labeling in fact corresponded 
most closely to a postsynaptic distr ibution (33,34). 'Aow then is this result 
reconciled with the expectation that stimulated labeling be presynaptic, based 
on the ultrastructural appearance of synaptosomes? We believe that the nerve 
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ending particles that mediate the effect contain postsynaptic membranes as an 
integral part of the plasma membrane. This wi l l  be the case i f  there is a 
presynaptic input to the nerve terminal, i . e . ,  that i t  is cho]inoceptive in 
addition to i t s e l f  being presynaptic to a third neuron (see Fig. 3). The 
nerve ending particle that mediates stimulated labeling could alternatively be 
a pinched-off dendrite, or "dendrosome" (35). 
In s t i l l  other studies, the pharmacologica] nature of the CNS muscarinic 
receptor has been studied by comparison of QNB-binding and percent stimulation 
of Phl and PhA labeling (Fisher, Klinger and Agranoff, in preparation). 
Muscarinic agents can be classified as strong and weak agonists in regard to 
their ab i l i t y  to stimulate l ip id  labeling. While they al l  displace QNB, the 
weak agonists have some antagonist act iv i ty .  High and low a f f in i ty  receptors 
can be identif ied, and the stimulated l ip id  labeling is found to correlate 
with occupation of the low a f f in i ty  sites. 
Whether the detailed operation of the stimulated l ip id  labeling in such 
diverse tissues as nerve ce]]s and platelets subserve the same or even similar 
purposes remains to be elucidated. For the present, one is more impressed by 
commonality than by differences, so that what is learned in one system is 
l ikely to have significance for another. 
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